Genprex (GNPX) stock Forecast for 2022 – 2026
Last update: 05-24-2022, 6:51Sector: Healthcare
The share price of Genprex, Inc. (GNPX) now
What analysts predict:: $6.5
52-week high/low: $4.07 / $1.17
50/200 Day Moving Average: $1.892 / $2.157
This figure corresponds to the average price over the previous 50/200 days. For Genprex stocks, the 50-day moving average is the resistance level today.
For Genprex stocks, the 200-day moving average is the resistance level today.
Are you interested in Genprex, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Genprex stock price in 2022, 2023, 2024, 2025, 2026. How much will one Genprex share be worth in 2022 - 2026?
When should I take profit in Genprex stock? When should I record a loss on Genprex stock? What are analysts' forecasts for Genprex stock? What is the future of Genprex stock?
We forecast Genprex stock performance using neural networks based on historical data on Genprex stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Genprex stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Genprex shares. This happens once a day.
Historical and forecast chart of Genprex stock
The chart below shows the historical price of Genprex stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Genprex stock price can be found in the table below.
Long-term forecasts by years.
Genprex daily forecast for a month
Genprex Daily Price Targets
Genprex Stock Forecast 05-26-2022.
Pessimistic target level: 1.65
Optimistic target level: 1.71
Genprex Stock Forecast 05-27-2022.
Pessimistic target level: 1.63
Optimistic target level: 1.71
Genprex Stock Forecast 05-28-2022.
Pessimistic target level: 1.59
Optimistic target level: 1.65
Genprex Stock Forecast 05-29-2022.
Pessimistic target level: 1.58
Optimistic target level: 1.61
Genprex Stock Forecast 05-30-2022.
Pessimistic target level: 1.58
Optimistic target level: 1.64
Genprex Stock Forecast 05-31-2022.
Pessimistic target level: 1.54
Optimistic target level: 1.60
GNPX (GNPX) Monthly Stock Prediction for 2022
Genprex forecast for this year
Genprex Stock Prediction for Jun 2022
An uptrend is forecast for this month with an optimal target price of $1.76045. Pessimistic: $1.68. Optimistic: $1.85
Genprex Stock Prediction for Jul 2022
An uptrend is forecast for this month with an optimal target price of $1.8872. Pessimistic: $1.68. Optimistic: $2.00
Genprex Stock Prediction for Aug 2022
An downtrend is forecast for this month with an optimal target price of $1.88116. Pessimistic: $1.78. Optimistic: $1.97
Genprex Stock Prediction for Sep 2022
An downtrend is forecast for this month with an optimal target price of $1.77582. Pessimistic: $1.59. Optimistic: $1.92
Genprex Stock Prediction for Oct 2022
An downtrend is forecast for this month with an optimal target price of $1.52578. Pessimistic: $1.39. Optimistic: $1.69
Genprex Stock Prediction for Nov 2022
An downtrend is forecast for this month with an optimal target price of $1.52578. Pessimistic: $1.42. Optimistic: $1.59
Genprex Stock Prediction for Dec 2022
An downtrend is forecast for this month with an optimal target price of $1.4794. Pessimistic: $1.42. Optimistic: $1.63
Genprex (GNPX) Monthly Stock Prediction for 2023
Genprex (GNPX) Monthly Stock Prediction for 2024
Genprex (GNPX) Monthly Stock Prediction for 2025
Genprex (GNPX) Monthly Stock Prediction for 2026
Genprex information and performance
Genprex, Inc. Is a clinical gene therapy company. The company is focused on developing oncology based on its new technology platform, including its initial candidate product, Oncoprex, immunogenotherapy or Oncoprex. Oncoprex consists of a tumor suppressor gene introduced into the cells of a patient, which has an immunomodulatory effect and is thus considered an immunogenic therapy. The gene is one of a number of genes licensed for therapeutic use by the University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing preclinical gene therapy licensed by the University of Pittsburgh Commonwealth Higher Education System, which has the potential to treat type 1 and type 2 diabetes. He is developing his candidate product for use with targeted therapy and immunotherapy for non-small cell lung cancer (NSCLC).
100 CONGRESS AVENUE, SUITE 2000, AUSTIN, TX, US
Market Capitalization: 72 327 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -11 505 661 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: None
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: N/A
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: -
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 47898400
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.